Antibe Therapeutics Inc. (“Antibe” or the “Corporation”) (TSXV: ATE, OTCQX: ATBPF) is pleased to announce that, as of today, common shares of the Corporation began trading in the United States on the OTCQX exchange under the ticker symbol “ATBPF”. Antibe’s common shares will continue to trade on the TSX Venture Exchange under the symbol "ATE".

The OTCQX marketplace offers informed and efficient trading for established, investor-focused Canadian, U.S., and global companies. OTCQX is the premier tier of the OTC markets. To qualify, companies must meet high financial standards, be current in their disclosure, and be sponsored by a professional third-party advisor. Merriman Capital Inc. serves as Antibe’s Principal American Liaison (“PAL”) responsible for providing professional guidance on OTCQX requirements.

Dr. Michael Bumby, Antibe's CFO said, "We view trading in the US on OTCQX as an important step in our capital markets strategy. It will significantly increase the accessibility of US investors as we continue to build our company and broaden our development portfolio."

Investors can find current financial disclosure and Real-Time Level 2 quotes for Antibe on

About Antibe Therapeutics Inc.

Antibe develops safer medicines for pain and inflammation.  Antibe’s technology involves linking a hydrogen sulfide-releasing molecule to an existing drug to produce a patented, improved medicine.  Antibe’s ATB-346 targets the global need for safer non-steroidal anti-inflammatory drugs (NSAIDs).

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Copyright Business Wire 2010